Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dormancy exit correlates with CREB1 reactivation that is a potential target to overcome endocrine therapy resistance in ER<sup>+</sup> breast cancer cells.

iScience·2026
Same author

Chromosome-level genome assembly and annotation of the endangered species Ormosia henryi.

Scientific data·2025
Same author

First report of transient urinary retention after bilateral lumbar ESPB in a patient with FBSS: a case report.

Frontiers in medicine·2025
Same author

Occurrence forms and transformation mechanisms of typical antibiotics in the aquatic environment of the Zaohe-Weihe River estuary.

Environmental geochemistry and health·2025
Same author

Isotopic Constraints on Seasonal Nitrogen Transformation Dynamics along a Deposition Gradient in Subtropical Forests.

Environmental science & technology·2025
Same author

Global burden of dengue from 1990 to 2021: a systematic analysis from the Global Burden of Disease study 2021.

Infectious diseases of poverty·2025

相关实验视频

Updated: Jun 3, 2025

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

14.7K

对MCL1抑制剂敏感性的潜在生物标志物

Lei Duan1, Carl G Maki1

  • 1Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL 60612, USA.

Cell signaling
|January 13, 2025
PubMed
概括

研究人员确定了一种四基因特征,可以预测三阴性乳腺癌 (TNBC) 中对MCL1抑制剂的耐药性. 这个签名可以指导接受MCL1抑制剂治疗的患者选择治疗.

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 癌症遗传学 癌症遗传学

背景情况:

  • 抗亡蛋白MCL1在许多癌症中过度表达,与预后不佳相关.
  • MCL1 抑制剂在治疗三阴性乳腺癌 (TNBC) 和其他恶性瘤方面表现有前途.
  • 耐药性和缺乏预测性生物标志物限制了MCL1抑制剂的临床疗效.

研究的目的:

  • 确定一个功能基因特征 (GS),预测TNBC中对MCL1抑制剂的耐药性.
  • 阐明 MCL1 抑制剂耐药性的基础分子机制.
  • 探索已识别的GS作为TNBC治疗预测生物标志物的潜力.

主要方法:

  • 对TNBC细胞系中基因表达的分析,对MCL1抑制剂的敏感性不同.
  • 与耐药性相关的四个基因特征的功能验证.
  • 研究ERK信号通路在阻力中介中的作用.

主要成果:

  • 确定了四个基因的特征,可以区分抗抑制剂的MCL1和敏感的TNBC细胞系.
  • 已识别的基因促进抵抗,部分通过调节ERK信号通路.
  • 这种机制涉及BCL2和BIM的改变表达,有助于耐药性.
关键词:
一个AXL一个AXL在EFEMP1的基础上,EFEMP在ETS1中,ETS1是ETS1.在IL6 IL6 IL6 IL6 IL6这是一种MCL1抑制剂.预测性标记物是一种预测标记物.三重阴性乳腺癌是什么?

更多相关视频

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.4K

相关实验视频

Last Updated: Jun 3, 2025

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

14.7K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.4K

结论:

  • 在TNBC中发现了一种功能性基因特征驱动MCL1抑制剂耐药性.
  • 这种特征可以作为患者对MCL1抑制剂反应的预测生物标志物.
  • 这些发现可以为结合疗法策略提供信息,以克服耐药性并改善治疗结果.